Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,
Grant
Overview
Affiliation
Overview
Awarded By
PUBLIC HEALTH INSTITUTE (PHI)
Total Award Amount
20150.00
Direct Costs
15500.00
Sponsor Award Id
Affiliation
Contributor
Aman Wadhwa
Investigator
Ana Xavier
Investigator
Julie Wolfson-Stockman M.D.
Investigator
Matthew Kutny M.D.
Principal Investigator